Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario Puerta de Hierro (25)

2024

  1. Role of TBX20 Truncating Variants in Dilated Cardiomyopathy and Left Ventricular Noncompaction

    Circulation: Genomic and Precision Medicine, Vol. 17, Núm. 2, pp. E004404

2023

  1. ROD2 domain filamin C missense mutations exhibit a distinctive cardiac phenotype with restrictive/hypertrophic cardiomyopathy and saw-tooth myocardium

    Revista Espanola de Cardiologia, Vol. 76, Núm. 5, pp. 301-311

2022

  1. Characterization of hereditary transthyretin cardiac amyloidosis in Spain

    Revista Espanola de Cardiologia, Vol. 75, Núm. 6, pp. 488-495

  2. Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry

    ESC Heart Failure, Vol. 9, Núm. 4, pp. 2189-2198

  3. Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator

    European heart journal, Vol. 43, Núm. 32, pp. 3053-3067

  4. Natural History of MYH7-Related Dilated Cardiomyopathy

    Journal of the American College of Cardiology, Vol. 80, Núm. 15, pp. 1447-1461

  5. Polymorphisms in ACE, ACE2, AGTR1 genes and severity of COVID-19 disease

    PLoS ONE, Vol. 17, Núm. 2 February

  6. The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy

    European Journal of Preventive Cardiology, Vol. 29, Núm. 4, pp. 645-653

2021

  1. Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy

    Journal of the American College of Cardiology, Vol. 78, Núm. 17, pp. 1682-1699

  2. Clinical Risk Prediction in Patients With Left Ventricular Myocardial Noncompaction

    Journal of the American College of Cardiology, Vol. 78, Núm. 7, pp. 643-662

  3. Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis of cardiomyopathy: The ESC EORP Cardiomyopathy/Myocarditis Registry

    European Heart Journal Cardiovascular Imaging, Vol. 22, Núm. 7, pp. 781-789

2020

  1. Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis

    Journal of the American College of Cardiology, Vol. 76, Núm. 2, pp. 186-197

  2. Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the TTN Gene

    Circulation: Heart Failure, Vol. 13, Núm. 10, pp. E006832

  3. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet, Vol. 396, Núm. 10253, pp. 759-769

  4. Mortality among Referral Patients with Hypertrophic Cardiomyopathy vs the General European Population

    JAMA Cardiology, Vol. 5, Núm. 1, pp. 73-80

2019

  1. Effectiveness of the 2014 european society of cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: A systematic review and meta-analysis

    Heart, Vol. 105, Núm. 8, pp. 623-631

2018

  1. Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy

    Journal of the American College of Cardiology, Vol. 72, Núm. 20, pp. 2457-2467

2017

  1. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation

    International Journal of Cardiology, Vol. 248, pp. 232-238

  2. Mid-range left ventricular ejection fraction: Clinical profile and cause of death in ambulatory patients with chronic heart failure

    International Journal of Cardiology, Vol. 240, pp. 265-270

  3. Predictors of atrial fibrillation in hypertrophic cardiomyopathy

    Heart, Vol. 103, Núm. 9, pp. 672-678